GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Imunon Inc.
Imunon is an oncology company. Its stock price is a bet on the success of its immunotherapy platform. Its price is volatile and driven by news of clinical trials and partnerships that help fund its expensive developments.
Share prices of companies in the market segment - Dna
Imunon, Inc. is a biotechnology company developing immunotherapeutic drugs and vaccines based on DNA technologies for the treatment of cancer and infectious diseases. We've classified it as a "DNA" company, and the chart below shows how the market views the prospects for this cutting-edge technology.
Broad Market Index - GURU.Markets
Imunon is a biotech company developing immunotherapeutic drugs and DNA vaccines for the treatment of cancer and infectious diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Imunon shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IMNN - Daily change in the company's share price Imunon Inc.
Imunon, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its DNA immunotherapy and vaccines.
Daily change in the price of a set of shares in a market segment - Dna
Imunon, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the dynamics of IMNN, which focuses on immunotherapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Imunon is a biotech company developing DNA-based drugs for the treatment of cancer and infectious diseases. Its shares move in sync with clinical trial news. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Imunon Inc.
For Imunon, Inc., year-over-year performance is the story of its cancer immunotherapy platform. Its 12-month market cap is entirely dependent on clinical trial data for its lead ovarian cancer drug. Success could validate the potential of its approach, which focuses on stimulating the immune system to fight tumors.
Annual dynamics of market capitalization of the market segment - Dna
Imunon, Inc. is a biotech company developing immunotherapies and vaccines. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Imunon, working in the cutting-edge field of DNA immunotherapy, is a pure bet on science. Its performance relative to the market reflects investors' expectations that its technology platform will prove effective in treating cancer and infectious diseases. Economics are irrelevant.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Imunon Inc.
Imunon is a biotech company focused on immunotherapy and DNA vaccines. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its oncology and infectious disease programs is the primary driver.
Monthly dynamics of market capitalization of the market segment - Dna
Imunon is a biotech company developing immunotherapeutic drugs and DNA vaccines for the treatment of cancer and infectious diseases. The chart below shows the overall dynamics of the biotech sector, where immunology remains one of the hottest areas of research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Imunon is a biotech company developing immunotherapy and DNA vaccines for cancer treatment. Its shares are a classic venture capital story. Their price moves on news of clinical trials and has no correlation with overall market trends, reflecting only the risks and hopes of the biotech industry.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Imunon Inc.
Imunon is a biopharmaceutical company developing immunotherapies and DNA vaccines. Its weekly stock price, typical for biotech companies, depends entirely on progress in clinical trials.
Weekly dynamics of market capitalization of the market segment - Dna
Imunon, Inc. operates in DNA medicine, a cutting-edge field in biotechnology. This chart helps separate the stock's unique reaction to the company's scientific publications and trial data from the overall sentiment in the gene therapy sector. How does its story stand out from the crowd?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Imunon, Inc. is an oncology biotech company. Its success depends on scientific breakthroughs. This chart clearly shows how often the company's shares move against the broader market in response to research data releases. How immune is it to overall market volatility?
Market capitalization of the company, segment and market as a whole
IMNN - Market capitalization of the company Imunon Inc.
The Imunon, Inc. chart is a visualization of the hopes in immunotherapy and DNA vaccines. This biotech company's market cap reflects investors' faith in its technology platforms for fighting cancer and infectious diseases. Its volatile curve reflects the response to clinical trial data.
IMNN - Share of the company's market capitalization Imunon Inc. within the market segment - Dna
Imunon is a biopharmaceutical company developing DNA-mediated immunotherapies and vaccines for the treatment of cancer and infectious diseases. In the cutting-edge DNA medicine segment, its market capitalization reflects the potential of its technological platform. The company's size reflects the success of its clinical programs and the versatility of its approach.
Market capitalization of the market segment - Dna
Imunon is an immuno-oncology company. How big is this arena? The chart below shows the pulse of the DNA technology sector. Its high volatility reflects both the enormous hopes for a new generation of cancer drugs and the high risks associated with their development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Imunon chart shows how the market values the development of immunotherapeutic drugs and DNA vaccines. Its market cap is a bet on the success of its technology platforms in treating cancer and infectious diseases. This chart is fraught with the scientific risk typical of early-stage biotech companies.
Book value capitalization of the company, segment and market as a whole
IMNN - Book value capitalization of the company Imunon Inc.
The book value of Imunon, an immunotherapy company, is its tangible capital, consisting of the rights to its technology platforms (TheraPlas, PLACCINE) and financial reserves for clinical trials. The chart below shows how this scientific and financial capital has changed.
IMNN - Share of the company's book capitalization Imunon Inc. within the market segment - Dna
Imunon, Inc. is an immunotherapy company whose tangible assets include laboratories and partner manufacturing facilities where its platforms for treating cancer and infectious diseases are developed. The chart shows the percentage of this specialized R&D and manufacturing infrastructure the company controls.
Market segment balance sheet capitalization - Dna
Imunon is an oncology company. The pharmaceutical industry, as the chart shows, is both knowledge- and capital-intensive. Imunon focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Imunon's assets are not drugs, but a scientific platform for developing DNA immunotherapies and vaccines for the treatment of cancer and infectious diseases. Its book value reflects its laboratory facilities and the capital invested in developing this cutting-edge technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Imunon Inc.
Imunon is a biotech company developing DNA-based immunotherapies for the treatment of cancer and infectious diseases. Its value lies in its technological platform. The chart shows how the market views its scientific approach and clinical trial progress.
Market to book capitalization ratio in a market segment - Dna
Imunon is a biotech company developing immunotherapeutic drugs and DNA vaccines. Its value depends on the success of clinical trials. The chart shows how the market values its scientific platforms (Threogene, PLACCINE) and their potential.
Market to book capitalization ratio for the market as a whole
Imunon, Inc. is working on DNA vaccines and immunotherapy. Like many biotechs, its valuation is a bet on the future success of clinical trials. This chart clearly demonstrates how market value in this sector is disconnected from book value and is entirely dependent on scientific data and expectations.
Debts of the company, segment and market as a whole
IMNN - Company debts Imunon Inc.
Imunon is a biotech company developing DNA-mediated immunotherapies and vaccines. This is a cutting-edge scientific field that requires long-term and significant investment in research and clinical trials. This chart shows how the company is raising capital to finance its innovative, but very expensive, scientific platform.
Market segment debts - Dna
Imunon is a clinical-stage oncology company developing DNA-based immunotherapies. Its future depends entirely on the results of clinical trials. This chart shows its cash reserves and how long it can fund its expensive research without raising new capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Imunon Inc.
Imunon, Inc. is a biotechnology company working in DNA therapeutics and immunology. This chart shows its financial structure. For a company engaged in cutting-edge but risky scientific research, any debt is a significant burden. All resources should be focused on research, not on interest payments.
Market segment debt to market segment book capitalization - Dna
Imunon is a biopharmaceutical company developing DNA-mediated immunotherapies and vaccines. This is a cutting-edge scientific field. The chart shows the overall debt burden in the sector, which helps understand how the company finances its long-term and capital-intensive research aimed at using DNA to stimulate the immune system.
Debt to book value of all companies in the market
Imunon, Inc. is an immuno-oncology company developing DNA vaccines against cancer. This is a cutting-edge, but risky, technology. This chart clearly shows that the debt market is closed to such companies at the forefront of science, and their survival and growth depend entirely on research results and shareholder support.
P/E of the company, segment and market as a whole
P/E - Imunon Inc.
For Imunon, a biopharmaceutical company working in immunotherapy and DNA vaccines, the P/E ratio is irrelevant. The company is not profitable, and its valuation on this chart is arbitrary. Its true value depends on the success of its clinical trials and the potential of its scientific platform.
P/E of the market segment - Dna
Imunon is a clinical-stage biopharmaceutical company developing immunotherapeutics and DNA-based vaccines for the treatment of cancer and infectious diseases. This chart shows the average valuation for the sector, providing investors with context for evaluating Imunon's scientific platform and portfolio.
P/E of the market as a whole
Imunon is a biopharmaceutical company developing immunotherapies and DNA vaccines. Its valuation is a pure bet on the success of its scientific platforms. It has no connection to the general economic cycles depicted by this chart. Imunon's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Imunon Inc.
Imunon is a biotech company developing DNA-based immunotherapeutics for the treatment of cancer and infectious diseases. This chart reflects investor expectations for its technology platform and clinical trials. The valuation is based on the long-term potential of this new approach to stimulating the immune system.
%20P%2FE%20Imunon%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Imunon-Inc.&v=1772619086638 "Chart of the company's future (projected) P/E Imunon Inc.")
Future (projected) P/E of the market segment - Dna
Imunon is a biotech company developing DNA vaccines and immunotherapies for the treatment of cancer and infectious diseases. Its valuation relative to other biotechs reflects investor sentiment on its technology platform, demonstrating the market's confidence in its ability to develop effective DNA-based therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772619086649 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Imunon is a biopharmaceutical company developing immunotherapeutic drugs and vaccines based on DNA technologies. Its research targets cancer and infectious diseases. This chart shows the overall investor risk appetite, which is a key factor in evaluating biotech companies with innovative but not yet commercialized platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619086652 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Imunon Inc.
Imunon is a biotech company developing DNA-based immunotherapeutic drugs for the treatment of cancer and infectious diseases. The financial indicators shown in the graph represent the costs of clinical trials of its technology platform. Success in the clinic will determine its future.
Profit of companies in the market segment - Dna
Imunon, Inc. is a biotechnology company developing immunotherapeutic drugs and DNA vaccines for the treatment of cancer and infectious diseases. This chart reflects the financial health of the DNA therapeutics sector, demonstrating how close this cutting-edge field is to developing commercially viable products or is still in the research phase.
Overall market profit
Imunon is a biopharmaceutical company developing DNA-based immunotherapeutics and vaccines. Its prospects depend entirely on the results of clinical trials and regulatory approval. The macroeconomic cycles depicted in this chart do not affect the scientific basis or potential of Imunon's technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Imunon Inc.
Imunon is a biotech company developing DNA-mediated immunotherapies and vaccines for the treatment of cancer and infectious diseases. Its future profit forecast depends on the success of clinical trials. This chart shows how analysts assess the potential of its technology platform for creating a new class of drugs.
%20profit%20of%20the%20company%20Imunon%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Imunon-Inc.&v=1772619086679 "Graph of future (projected) profit of the company Imunon Inc.")
Future (predicted) profit of companies in the market segment - Dna
Imunon is a biopharmaceutical company developing immunotherapeutic drugs and vaccines based on DNA technologies for the treatment of cancer and infectious diseases. This chart shows forecasts for this segment. It illustrates the high risk and scientific complexity, but also the enormous potential of DNA therapy for the creation of a new generation of drugs and vaccines.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772619086686 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
For Imunon, a biopharmaceutical company working in DNA therapeutics, this chart is an indicator of the investment climate. Expectations of economic growth increase investors' risk appetite, making it easier to raise funds for expensive research. During downturns, biotech financing becomes more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619086689 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Imunon Inc.
Imunon is a biopharmaceutical company working on cancer immunotherapy and vaccines. This metric reflects investors' assessment of its scientific platform, predicting future revenue from licensing or sales of its drugs.
P/S market segment - Dna
Imunon is a biopharmaceutical company developing DNA-mediated immunotherapies and vaccines for the treatment of cancer and infectious diseases. This chart shows the average valuation of the DNA technologies sector. It reflects investor confidence in the potential of Imunon's innovative platform for stimulating the immune system to fight disease.
P/S of the market as a whole
Imunon, Inc. is an immuno-oncology company developing DNA-mediated immunotherapeutics and vaccines for cancer treatment. The company's valuation is based on the potential of its technology platform. This chart, showing the average revenue estimate, emphasizes that investing in such companies is an investment in the future of science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Imunon Inc.
Imunon is a biotech company developing immunotherapeutic drugs and DNA vaccines against cancer and infectious diseases. Its valuation is dependent on the success of clinical trials. The chart reflects investors' faith in its technology platform and ability to develop effective treatments.
%20P%2FS%20Imunon%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Imunon-Inc.&v=1772619086734 "The graph of the company's future (projected) P/S Imunon Inc.")
Future (projected) P/S of the market segment - Dna
Imunon, Inc. (formerly Celsion) is a biotech company developing immunotherapies and DNA vaccines for the treatment of cancer and infectious diseases. Its platforms are aimed at stimulating the body's immune response. This chart shows how investors view the potential of its research and development compared to other companies in the field.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772619086736 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
This indicator summarizes expectations for the biotech sector. For Imunon, a company developing DNA vaccines and immunotherapies, it reflects investor appetite for innovation. Market optimism allows for funding of advanced platforms that can be applied to the treatment of cancer and infectious diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619086738 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Imunon Inc.
Imunon is a clinical-stage biotechnology company developing DNA-based immunotherapeutics for the treatment of cancer and infectious diseases. This chart reflects revenue from grants and partnerships. Future revenue is dependent on the success of clinical trials of its TheraPlas platform and DNA vaccine technology.
Sales of companies in the market segment - Dna
Imunon, Inc. is an immuno-oncology company developing DNA-mediated immunotherapies and vaccines for the treatment of cancer and infectious diseases. This chart shows the growth of the gene therapy sector. Imunon's platforms are aimed at stimulating the immune system to fight disease, one of the most advanced areas in modern biomedicine.
Overall market sales
Imunon, Inc. is an immuno-oncology company developing DNA-mediated cancer treatments. Its market capitalization depends on progress in clinical trials. The overall economic environment, shown in this chart, influences the availability of capital to fund cutting-edge but risky therapeutic approaches.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Imunon Inc.
Imunon (formerly Celsion) is a biopharmaceutical company developing immunotherapy drugs and DNA vaccines against cancer and infectious diseases. Its future depends on the success of clinical trials of its technology platforms. This chart reflects analysts' assessments of the scientific potential and commercial prospects of the company's developments.
%20sales%20of%20the%20company%20Imunon%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Imunon-Inc.&v=1772619086771 "Schedule of future (projected) sales of the company Imunon Inc.")
Future (projected) sales of companies in the market segment - Dna
Imunon is a biotechnology company developing DNA-mediated immunotherapeutics and vaccines. This chart shows expectations for the DNA technology sector. It illustrates the potential of using genetic material to stimulate the immune system in the fight against cancer and infectious diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772619086773 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Imunon, Inc. is a clinical-stage biopharmaceutical company specializing in the development of DNA-mediated immunotherapeutics and vaccines. Its future depends on the success of clinical trials. The overall economic situation, reflected in this chart, influences the amount of public and private funding allocated to the development of innovative vaccines and treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619086780 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Imunon Inc.
Imunon is a biotech company developing DNA-mediated immunotherapies and vaccines. This chart reflects the company's financial performance during clinical trials. Negative values represent investments in developing a platform that could be used to create drugs for cancer and infectious diseases.
Market segment marginality - Dna
Imunon, Inc. is an immunotherapy company developing DNA vaccines and cancer treatments. For a company in clinical trials, this chart is an indicator of potential. It reflects the average profitability in the sector that Imunon could achieve if its innovative platforms are successful and regulatory approval is obtained.
Market marginality as a whole
Imunon is a biopharmaceutical company developing immunotherapeutic drugs based on DNA technologies. This total market profitability chart does not reflect its research activities. Its potential lies in the development of a new class of drugs for the treatment of cancer and infectious diseases. Success depends on the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Imunon Inc.
Imunon is a biotech company developing DNA-mediated immunotherapies and vaccines for the treatment of cancer and infectious diseases. This graph shows the small scientific team advancing its platform technologies through clinical trials.
Share of the company's employees Imunon Inc. within the market segment - Dna
Imunon, Inc. develops DNA-mediated immunotherapies and vaccines. In this cutting-edge field of biotechnology, its team of scientists shapes the company's future. This metric reflects the percentage of leading immunologists and molecular biologists working with DNA technologies that Imunon attracts, demonstrating its concentration of unique scientific expertise.
Number of employees in the market segment - Dna
Imunon, Inc. is a biopharmaceutical company developing immunotherapeutic drugs and DNA vaccines. Using DNA to "train" the immune system is one of the most promising areas. This graph demonstrates how science-intensive modern immunology has become, requiring the involvement of geneticists and molecular biologists to create next-generation vaccines.
Number of employees in the market as a whole
Imunon, Inc. specializes in DNA technologies, being at the cutting edge of biomedical science. This graph illustrates current employment, but it is these breakthrough companies that shape the future landscape. Their research could lead to the creation of entire new medical fields, driving a wave of demand for a new generation of specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Imunon Inc. (IMNN)
Imunon is a biotech company working in DNA therapeutics for the treatment of cancer and infectious diseases. This chart represents the net intellectual capital valuation. The company's value is based on its technology platforms (TheraPacc, PLACCINE). The chart shows how highly the market values this scientific potential per scientist.
%20of%20the%20company%20Imunon%20Inc.%20(IMNN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Imunon-Inc.-IMNN&v=1772619086827 "Chart of market capitalization per employee (in thousands of dollars) of the company Imunon Inc. (IMNN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Imunon, Inc. is working on DNA vaccines and immunotherapy. This is at the cutting edge of biotechnology, where market capitalization reflects belief in the scientific platform. The chart shows the market's attribution to each researcher on the team, allowing for a comparison of the investment attractiveness of their approach with other gene therapy companies.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772619086831 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Imunon, Inc. is a biopharmaceutical company developing DNA-mediated immunotherapies and vaccines. This chart reflects the market's perceived value per employee, highlighting the company's high valuation of its cutting-edge scientific platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619086842 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Imunon Inc. (IMNN)
Imunon is a biotech company developing DNA-mediated therapies. It is a clinical-stage R&D company. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to advance its platform and conduct clinical trials.
%20Chart%20Imunon%20Inc.%20(IMNN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Imunon-Inc.-IMNN&v=1772619086852 "Company Profit Per Employee (in thousands of dollars) Chart Imunon Inc. (IMNN)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Imunon, Inc. is a biopharmaceutical company developing DNA-mediated immunotherapeutics for the treatment of cancer and infectious diseases. Its core assets are its scientific platform and research team. For such companies in the clinical development stage, this graph typically shows negative profit per employee, reflecting high R&D costs.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772619086855 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Imunon (IMNN) is a clinical-stage biotech company developing immunotherapies and DNA-based vaccines for the treatment of cancer (such as ovarian cancer) and infectious diseases. It's an R&D company. This chart shows the market average dollar return per employee. For IMNN (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619086859 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Imunon Inc. (IMNN)
Imunon is an immunotherapy company developing DNA-based drugs for the treatment of cancer and infectious diseases. This chart demonstrates the potential of cutting-edge science. For a company in the development stage, it is an indicator of the future revenue that could be generated if its platform is successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Imunon-Inc.-IMNN&v=1772619086866 "Sales chart per company employee Imunon Inc. (IMNN)")
Sales per employee in the market segment - Dna
Imunon is a clinical-stage biotech company focused on DNA therapeutics for cancer and infectious diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Imunon's staff.
Sales per employee for the market as a whole
Imunon is a biotech company developing DNA vaccines and immunotherapies for cancer treatment. The company has no commercial products and, therefore, no revenue from them. This metric is currently irrelevant. The company's entire value lies in its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Imunon Inc. (IMNN)
Imunon is a biotech company developing DNA vaccines and immunotherapies for cancer treatment. This is a speculative field with a long history of failures. This chart shows the bets that their technology will be ineffective. "Bears" believe their platform will fail to prove its value in clinical trials, and the company will run out of money.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Imunon-Inc.-IMNN&v=1772619086932 "Short Shares Chart for the Company Imunon Inc. (IMNN)")
Shares shorted by market segment - Dna
Imunon, Inc. is a biotech company developing cancer immunotherapy and infectious disease vaccines using its DNA platform. This chart reflects the total short position in the biotech sector (DNA therapeutics). High values indicate general investor skepticism about the success of clinical trials and the commercialization of DNA-based technologies.
Shares shorted by the overall market
Imunon is a clinical-stage biotech betting on DNA therapy for cancer. Its price reflects the hope for a future breakthrough. This chart illustrates the overall market pessimism. When fear dominates, investors are unwilling to pay for R&D. They sell off shares of pre-profitable companies like IMNN, preferring to cash out until the market calms down.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Imunon Inc. (IMNN)
Imunon, Inc. is a biotech company working on DNA immunotherapy for cancer treatment. Like many in the sector, the company's shares react sharply to news. This oscillator measures the strength of these reactions, helping to identify when investor enthusiasm (above 70) about trial data or their fears (below 30) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Imunon-Inc.-IMNN&v=1772619086935 "RSI 14 indicator chart for the company's stock Imunon Inc. (IMNN)")
RSI 14 Market Segment - Dna
Imunon, Inc. is a biotech company developing DNA-based immunotherapeutics for the treatment of cancer (such as ovarian cancer). This chart measures the collective excitement or decline across the entire gene therapy and oncology industry. It helps determine whether the entire speculative segment is overheated by expectations of clinical success or oversold by competitors' unsuccessful trials.
RSI 14 for the overall market
For Imunon, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMNN (Imunon Inc.)
Imunon is a biotech company developing DNA vaccines and immunotherapies for the treatment of cancer (such as ovarian cancer) and infectious diseases. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet on the success of their DNA platform in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMNN-Imunon-Inc.&v=1772619086938 "A chart showing analyst consensus forecasts for the expected stock price. IMNN (Imunon Inc.)")
The difference between the consensus estimate and the actual stock price IMNN (Imunon Inc.)
Imunon is a biotech company developing DNA vaccines and immunotherapies (TheraPlas platform) for cancer treatment. This chart shows the difference between the market valuation and the consensus forecast. It reflects whether experts believe in their R&D approach and their ability to bring their drugs to clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMNN-Imunon-Inc.&v=1772619086943 "A chart showing the difference between the consensus forecast and the actual stock price. IMNN (Imunon Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Imunon is a biotech R&D company developing DNA vaccines (the TheraPlas platform) for cancer immunotherapy. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire DNA technology sector. It shows whether experts believe in the success of gene-based cancer vaccines.
Analysts' consensus forecast for the overall market share price
Imunon is a biotech company specializing in the development of DNA vaccines and immunotherapies for the treatment of cancer and infectious diseases. This chart reflects the overall market "risk appetite." For Imunon, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Imunon Inc.
Imunon is a biotech R&D company with a dual platform. They are developing DNA vaccines (for cancer and infections) and (more advanced) DNA therapy (TheraPlas) for ovarian cancer. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Dna
Imunon (IMNN) is a biotech company developing DNA-based immunotherapeutics. Their platforms (TheraPher, PlaStable) are used to create vaccines against cancer and infectious diseases. The chart shows the segment average, helping investors assess how this gene therapy technology compares to the sector average.
The AKIM Index for the overall market
Imunon is a biotech company developing DNA plasmid technologies for cancer immunotherapy (GEN-1) and vaccines. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific gene delivery platform compares to overall economic trends and clinical progress.
